US Stock MarketDetailed Quotes
VSTM Verastem
- 4.0000
- +0.0700+1.78%
Close Nov 22 16:00 ET
- 4.0900
- +0.0900+2.25%
Post 20:01 ET
178.03MMarket Cap-1273P/E (TTM)
4.1450High3.8050Low694.44KVolume3.9300Open3.9300Pre Close2.79MTurnover2.29%Turnover RatioLossP/E (Static)44.51MShares14.220052wk High16.06P/B121.52MFloat Cap2.100052wk Low--Dividend TTM30.38MShs Float225.8400Historical High--Div YieldTTM8.65%Amplitude2.1000Historical Low4.0120Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Verastem Stock Forum
Pretty damn good run so far. I only managed to hop on in Sept.
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumabPatients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months)...
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinibcombination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response ...
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/G...
No comment yet